Read our Recent Headlines


April 28 Biotech Update

We have a little bit of news this morning. There is no way I can cover it all especially having a bunch of conference calls to listen to as well..

April 27 Biotech Update

This week seems to have started like last week. I think it was actually last Tuesday that the sector suddenly took a dive on no real news and yesterday was.

April 25 Biotech Update

There is not a lot of news to start the week but this will be a bust week of news, so I will keep this short as we wait for.

April 22 Biotech Update

Yesterday was a great day for the sector (although volumes could have been better) but I do not know why. There did not seem to be a major catalyst but.

April 21 Biotech Update

I think the best description of the sector is listless and uncertain. The price action has been mixed but more than anything else, there has been a significant lack of.

April 20 Biotech Update

I need to get this out early as I have meetings all morning. I apologize if it does not read well or is poorly edited. 1. One worry that cannot.

April 18 Biotech Update

There is a recurring theme with excitement to end the week but no merger Monday. I continue to believe we are still too early for there to be a pick-up.

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!